根据《公司法》、《公司章程》的规定，何源先生的辞职导致公司董事会成 员低于法定人数，为保证公司各项业务正常开展，何源先生仍将继续履行公司董 事职责至公司股东大会选举出新任董事。 证券代码：300203 证券简称：聚光科技 公告编号：2023-040 聚光科技（杭州）股份有限公司 关于董事辞职暨补选非独立董事候选人的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、关于公司董事辞职的情况 聚光科技（杭州）股份有限公司（以下简称"公司"）董事何源先生因个人 工作原因，特申请辞去公司董事、董事会专门委员会等相关职务。何源先生辞去 上述职务后不再担任公司其他职务。 候选人简历： 韩双来先生，1980 年出生，中国国籍，无境外永久居留权，毕业于天津大 学测试计量技术及仪器专业，硕士研究生学历。2006 年 3 月-至今，供职于聚光 科技（杭州）股份有限公司，先后担任研发工程师，研发技术经理，产品经理， 研发总监，事业部总经理职务，现任聚光科技（杭州）股份有限公司总经理、公 司环境与科技仪器事业部总经理、公司控股子公司杭州谱育科技发展有限公司董 事长、总经理。 截至本公 ...

证券代码：300203 证券简称：聚光科技 公告编号：2023-037 聚光科技（杭州）股份有限公司 第四届董事会第九次会议决议公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 三、审议通过了《关于终止 2022 年员工持股计划的议案》 自公司 2022 年员工持股计划完成相关审议程序以来，公司管理层一直积极 推进持股计划的实施工作，多次与员工代表沟通本次员工持股计划的具体实施事 宜。考虑到公司层面 2022 年度业绩考核目标未实现，为更好地维护公司、股东 和员工的利益，公司依据《关于上市公司实施员工持股计划试点的指导意见》、 《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运 作》、公司《2022 年员工持股计划（草案）》等有关规定，2022 年员工持股计 划到期失效。具体内容详见中国证监会指定信息披露网站披露的《关于终止 2022 年员工持股计划的公告》。公司独立董事对该项议案发表了独立意见。 审议该项议案时，关联董事顾海涛、何源作为员工持股计划参与对象，对本 议案回避表决。 聚光科技(杭州)股份有限公司(下称"公司")董事会于2023年 ...

独立董事对相关事项发表的独立意见 根据中国证监会《上市公司独立董事规则》、《上市公司治理准则》、《深圳证 券交易所创业板股票上市规则》、《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》和《公司章程》等有关规定，我们作为聚光科 技（杭州）股份有限公司（以下简称"公司"）的独立董事，基于独立判断的立 场，本着对公司、全体股东和投资者负责的态度，秉持实事求是的原则，对第四 届董事会第九次会议的相关事项发表如下独立意见： 聚光科技(杭州)股份有限公司 经审核，公司终止2022年员工持股计划不存在损害公司及全体股东利益的情 形，不存在违反《公司法》、《证券法》、《关于上市公司实施员工持股计划试点的 指导意见》、《深圳证券交易所上市公司自律监管指引第2号——创业板上市公司 规范运作》等法律、法规及规范性文件的规定。因此，我们一致同意公司终止2022 年员工持股计划，并同意将此议案提交公司股东大会审议。 （以下无正文，为签字页） 一、关于控股股东及其他关联方占用公司资金、关联交易及公司对外担保情 况的专项说明和独立意见 根据中国证监会《关于规范上市公司与关联方资金往来及上市公司对外担保 若干问题的 ...

聚光科技（杭州）股份有限公司 第四届监事会第七次会议决议公告 本公司及监事会全体成员保证公告内容真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 聚光科技(杭州)股份有限公司(下称"公司") 监事会于2023年8月19日以电 子邮件、书面传真和专人送达等方式发出召开公司第四届监事会第七次会议通 知。本次会议于2023年8月25日以通讯表决的方式召开。本次会议应参加表决3 人，实际参加表决3人，本次会议的召集、召开符合《中华人民共和国公司法》 和公司章程的有关规定，会议决议合法、有效。监事会以通讯方式(传真)表决通 过了以下议案: 证券代码：300203 证券简称：聚光科技 公告编号：2023-038 监事赵玲、韦俊峥、程婷婷均是本员工持股计划的参与人，为关联监事，在 审议本议案时应回避表决。关联监事回避表决后，监事会对本议案无法形成有效 决议，本议案直接提交公司2023年第一次临时股东大会审议。 特此公告。 聚光科技（杭州）股份有限公司监事会 二〇二三年八月二十九日 一、审议通过了《关于 2023 年半年度报告及摘要的议案》 经审核，监事会认为董事会编制和审核公司 2023 年半年度报告的程序符合 法 ...

1、股东大会届次：2023年第一次临时股东大会。 2、会议召集人：公司董事会 证券代码：300203 证券简称：聚光科技 公告编号：2023-042 聚光科技（杭州）股份有限公司 关于召开2023年第一次临时股东大会的通知 本公司及董事会全体成员保证公告内容真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 经本公司第四届董事会第九次会议审议通过，聚光科技（杭州）股份有限公 司定于2023年9月13日14:30在杭州市滨江区滨安路760号聚光科技（杭州）股份 有限公司会议室召开公司2023年第一次临时股东大会。现将有关事项通知如下： 一、召开会议基本情况： 3、会议召开的合法、合规性：经公司第四届董事会第九次会议审议通过决 定召开2023年第一次临时股东大会，召集程序符合有关法律、行政法规、部门规 章、规范性文件和公司《章程》的规定。 4、会议召开时间 现场会议时间：2023年9月13日14:30 网络投票时间：2023年9月13日 其中，通过深圳证券交易所交易系统进行网络投票的时间为2023年9月13日 上午9:15-9:25，9：30-11：30，下午13：00-15：00；通过深圳证券交易所互联 ...

Financial Performance - The company's revenue for Q1 2023 was ¥519,460,164.32, representing a 3.40% increase compared to ¥502,355,777.57 in Q1 2022[4] - The net loss attributable to shareholders was ¥87,328,471.36, a 47.92% increase from a loss of ¥59,036,738.82 in the same period last year[4] - Basic and diluted earnings per share were both -¥0.195, a decrease of 46.62% from -¥0.133 in the previous year[4] - Net loss for Q1 2023 was CNY 102,510,457.16, compared to a net loss of CNY 77,955,863.57 in Q1 2022, reflecting a deterioration in performance[23] - The company reported a total comprehensive loss of CNY 102,485,693.93 for Q1 2023, compared to a loss of CNY 79,760,432.91 in the previous year[23] Cash Flow and Operating Activities - The net cash flow from operating activities improved by 59.95%, amounting to -¥149,214,873.49 compared to -¥372,615,164.88 in Q1 2022[4] - Cash flow from operating activities showed a net outflow of CNY 149,214,873.49, an improvement from a net outflow of CNY 372,615,164.88 in Q1 2022[25] - Cash and cash equivalents at the end of Q1 2023 were CNY 1,142,691,786.97, compared to CNY 965,022,381.56 at the end of Q1 2022[26] - The company received CNY 425,310,222.02 in borrowings during Q1 2023, slightly up from CNY 424,000,000.00 in the same period last year[26] - The company’s total cash inflow from financing activities was CNY 446,193,733.87, compared to CNY 424,000,000.00 in Q1 2022[26] Assets and Liabilities - Total assets at the end of Q1 2023 were ¥10,347,737,705.98, a 0.59% increase from ¥10,287,367,777.32 at the end of the previous year[4] - The company's total liabilities reached approximately 6.91 billion RMB, compared to 6.74 billion RMB at the beginning of the year[20] - The company's total equity decreased to approximately 3.44 billion RMB from 3.55 billion RMB at the beginning of the year[20] - The company's current assets totaled approximately 4.62 billion RMB, slightly up from 4.58 billion RMB at the beginning of the year[19] - The company's inventory increased to approximately 1.48 billion RMB from 1.35 billion RMB at the beginning of the year[19] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 12,504[12] - The top shareholder, Zhejiang Ruiyang Technology Co., Ltd., holds 16.18% of the shares, with 73,228,185 shares pledged[13] Subsidiary Performance - The company achieved a total new contract amount of approximately 500 million RMB in the reporting period, with its subsidiary Hangzhou Puyu Technology Development Co., Ltd. contributing about 210 million RMB[17] - In Q1 2023, Puyu Technology reported revenue of 226 million RMB, with a net loss of 29.95 million RMB[17] Operating Costs and Expenses - Total operating costs rose to CNY 689,802,271.39, up 8% from CNY 638,851,659.23 in the previous year[22] - Research and development expenses increased to CNY 157,676,474.91, up 13.5% from CNY 138,873,659.51 in the same period last year[22] Other Income and Investment - Other income increased by 39.49% to ¥39,167,722.25, primarily due to an increase in government subsidies[10] - Investment income showed a loss of ¥6,822,704.61, worsening by 43.32% from a loss of ¥4,760,494.04 in the previous year[10] Audit Status - The first quarter report of the company is unaudited[27]

Financial Performance - The company's operating revenue for 2022 was 3.45 billion RMB, a decrease of 8% compared to the previous year[5]. - The net profit attributable to shareholders, after deducting non-recurring gains and losses, was -419 million RMB, a decline of 18.96% year-on-year, with losses increasing by 67 million RMB compared to the previous year[5]. - The company's operating revenue for 2022 was ¥3,450,620,276.09, a decrease of 8.00% compared to ¥3,750,514,066.26 in 2021[25]. - The net profit attributable to shareholders was -¥374,816,820.15, representing a decline of 61.25% from -¥232,438,571.77 in the previous year[25]. - The cash flow from operating activities improved significantly, with a net cash flow of -¥11,995,832.70, an increase of 96.72% compared to -¥366,149,530.54 in 2021[25]. - The basic and diluted earnings per share were both -¥0.8400, down 61.54% from -¥0.5200 in 2021[25]. - The net assets attributable to shareholders decreased by 8.15% to ¥3,228,756,373.83 from ¥3,515,301,302.78 in 2021[25]. - The company has faced uncertainty regarding its ability to continue as a going concern, as indicated by the negative net profits over the last three years[25]. Contracts and Revenue Sources - The total amount of new contracts signed by the company was approximately 4.6 billion RMB, an increase of about 12.2% year-on-year, with the subsidiary Puyutech contributing approximately 2.12 billion RMB, a growth of 58.2%[5]. - The main business revenue was CNY 3.32 billion, accounting for 96.35% of total revenue, with a year-on-year decrease of 8.28%[83]. - The revenue from instruments and related software was CNY 2.35 billion, representing 68.18% of total revenue, with a year-on-year increase of 12.76%[83]. - Domestic revenue was CNY 3.35 billion, down 9.39% year-on-year, while international revenue increased by 92.31% to CNY 99 million[81]. Research and Development - The company plans to increase R&D investment and market promotion for new products, leading to an increase in financial expenses due to rising interest-bearing debt[5]. - The company has invested a total of 3 billion RMB in R&D, maintaining a high proportion of investment to accelerate technology platform accumulation[79]. - The total R&D investment for 2022 was approximately ¥566.33 million, representing 16.41% of the operating revenue, an increase from 13.95% in 2021[93]. - The number of R&D personnel increased by 16.07% to 1,726 in 2022, accounting for 24.54% of the total workforce[93]. - The company is advancing multiple R&D projects, including a clinical protein analysis system and a digital fluorescence immunoassay system, both of which are in the market promotion phase[92]. Product Development and Innovation - The company is focused on the development of high-end analytical instruments, which are crucial for scientific research and technological innovation[36]. - The company has developed a series of new monitoring devices for environmental applications, including photochemical and greenhouse gas monitoring systems[40]. - The company has launched a new online monitoring system for emerging water pollutants, utilizing triple quadrupole mass spectrometry technology[43]. - The company has established a comprehensive carbon monitoring solution, integrating monitoring, data analysis, and simulation processes[44]. - The company has launched multiple innovative products in the high-end scientific instrument sector, achieving substantial sales growth and maintaining a leading position in technology and market[63]. Financial Management and Governance - The company does not plan to distribute cash dividends, issue bonus shares, or increase share capital from reserves[7]. - The company has established a transparent performance evaluation and incentive mechanism for senior management, adhering to legal standards[126]. - The company maintains independence from its controlling shareholders in business, assets, personnel, and finance[128]. - The company has implemented a comprehensive salary and performance assessment system for its management team[139]. - The company emphasizes legal operation and integrity in tax payment, focusing on creating economic value while fulfilling social responsibilities[165]. Risks and Challenges - The company faces various risks including technology, market, accounts receivable, expansion, mergers and acquisitions, human resources, and PPP project risks[6]. - The company is addressing accounts receivable risks, as a significant portion of its total assets is tied up in receivables from government and large industrial clients[114]. - The company is enhancing its internal audit and control systems to mitigate management and operational risks associated with rapid expansion[116]. - The company is cautiously pursuing new mergers and acquisitions, having established a specialized acquisition team and an initial integration management system[117]. Market Position and Strategy - The global analytical instrument market is experiencing stable growth, with China’s market share increasing rapidly despite being relatively small[109]. - The company aims to enhance its competitiveness in the analytical instrument sector by integrating production, learning, research, and application, focusing on core technology platforms[111]. - The company plans to develop a series of innovative products tailored to high-end, diverse, and customized analytical detection needs[112]. - The company is committed to accelerating the domestic research and development and localization process of high-end analytical instruments[111]. Corporate Social Responsibility - The company respects and protects the rights of stakeholders, promoting mutual benefits with suppliers and customers[127]. - The company adheres to labor laws to protect employee rights and interests, fostering a harmonious labor relationship[166]. - The company has committed to not engaging in any competitive business or product development that may conflict with its own operations[170].

本公司及董事会全体成员保证信息披露的内容真实、准确和完整， 没有虚假记载、误导性陈述或重大遗漏。 聚光科技（杭州）股份有限公司（以下简称"公司"）定于2023年5月5日（周 五）15:00-17:00在全景网举办2022年度业绩说明会，本次年度业绩说明会将采 用网络远程的方式举行，投资者可登陆全景网"投资者关系互动平台" （https://ir.p5w.net）参与本次年度业绩说明会或者直接进入聚光科技（杭州） 股份有限公司路演厅（https://ir.p5w.net/c/300203.shtml）参与本次年度业 绩说明会。 聚光科技（杭州）股份有限公司 关于举行2022年度网上业绩说明会的公告 出席本次说明会的人员有：公司董事长顾海涛先生、总经理韩双来先生、财 务负责人虞辉先生、董事会秘书田昆仑先生、独立董事刘菁女士。 为充分尊重投资者、提升交流的针对性，现就公司 2022 年度业绩说明会提 前向投资者公开征集问题，广泛听取投资者的意见和建议。投资者可于 2023 年 5 月 5 日（星期五）15：00 前访问 https://ir.p5w.net/zj/，或扫描下方二维 码，进入问题征集专题页面。公司将在 ...